This is the publication of one of the projects we (the Musella Foundation) helped fund. The concept is perfect and elegant - select the best treatment plan for a child with DIPG based on the biological makeup of the tumor. Each patient was reviewed by a board of experts and they decided on up to 4 approved drugs to use in combination to treat the kids. This is similar to how our patient navigation program works except we do not limit ourselves to approved treatments.
They did learn a few things as noted in the article, which lays the groundwork for the next iteration of this project Unfortunately they can not yet use treatments like Onc-201 or DCVAX because they are not approved yet. Hopefully that will change soon.